Hedegaard, H., Miniño, A. M., and Warner, M., “Drug Overdose Deaths in the United States, 1999–2018,” National Center for Health Statistics Data Brief, January 2020 [cited 2021 Sept 24] no. 356, available at <https://www.cdc.gov/nchs/products/databriefs/db356.htm> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Ahmad, F. B., Cisewski, J. A., Rossen, L. M., and Sutton, P., “Provisional Drug Overdose Death Counts,” National Center for Health Statistics, June 14, 2023 [cited 2023 June 30], available at <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm> (last visited June 30, 2023).+(last+visited+June+30,+2023).>Google Scholar

National Academies of Sciences, Engineering, and Medicine, “Medications for Opioid Use Disorder Save Lives,” The National Academies Press, 2019 [cited 2021 Sept 24], available at <https://doi.org/10.17226/25310> (last visited June 1, 2023).CrossRef+(last+visited+June+1,+2023).>Google Scholar

Id; Wakeman, S. E., Larochelle, M. R., and Amel, O., et al., “Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder,” JAMA Network Open 3, no. 2 (2020): e1920622, doi: 10.1001/jamanetworkopen.2019.20622.CrossRefGoogle ScholarPubMed

Winograd, R. P., Presnall, N., and Stringfellow, E. et al., “The Case for a Medication First Approach to the Treatment of Opioid Use Disorder,” American Journal of Drug and Alcohol Abuse 45, no. 3(2019): 333–340, available at <https://pubmed.ncbi.nlm.nih.gov/31084515/ doi: 10.1080/00952990.2019.1605372>; A. Sharma, M. K. Sharon, and G. M. Shannon et al., “Update on Barriers to Pharmacotherapy for Opioid Use Disorders,” Current Psychiatry Report 19, no. 6(2017): 35, available at <https://pubmed.ncbi.nlm.nih.gov/28526967/ doi: 10.1007/s11920-017-0783-9> (last visited June 1, 2023).CrossRefGoogle Scholar

Krawczyk, N. et al., “Has the Treatment Gap for Opioid Use Disorder Narrowed in the U.S.? A Yearly Assessment from 2010 to 2019,” International Journal of Drug Policy 110 (2022): 103786, doi: 10.1016/j.drugpo.2022.103786; P. M. Mauro, S. Gutkind, and E. M. Annunziato, et al., “Use of Medication for Opioid Use Disorder Among US Adolescents and Adults with Need for Opioid Treatment,” JAMA Network Open 5, no. 3 (2019): e223821, doi: 10.1001/jamanetworkopen.2022.3821; A. S. Huhn, et al., “Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States,” JAMA Network Open 3, no. 2 (2020): e1920843, doi: 10.1001/jamanetworkopen.2019.20843; S. E. Wakeman, et al., “Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder,” JAMA Network Open 3, no. 2 (2020): e1920622, doi: 10.1001/jamanetworkopen.2019.20622.CrossRefGoogle ScholarPubMed

Smart, R., Grant, S., and Gordon, A. J. et al., “Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder,” JAMA Health Forum 3, no. 9 (2022): e223285, doi: 10.1001/jamahealthforum.2022.3285.CrossRefGoogle Scholar

21 U.S.C. § 823(g)(1); 42 C.F.R. § 8.11(a).Google Scholar

42 C.F.R. § 8.12.Google Scholar

Substance Abuse and Mental Health Services Administration. Opioid Treatment Program (OTP), available at <https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Pessar, S. C., Boustead, A., and Ge, Y., et al., “Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond,” JAMA Health Forum 2, no. 11(2021): e213833. doi: 10.1001/jamahealthforum.2021.3833.CrossRefGoogle ScholarPubMed

Amram, O. et al., “Changes in Methadone Take-Home Dosing Before and After COVID-19,” Journal of Substance Abuse Treatment 133 (2022): 108552, doi: 10.1016/j.jsat.2021.108552; M. C. Figgatt et al., “Take-Home Dosing Experiences Among Persons Receiving Methadone Maintenance Treatment During COVID-19,” Journal of Substance Abuse Treatment 123 (2021): 108276, doi: 10.1016/j.jsat.2021.108276; L. W. Suen et al., “’The Idea is to Help People Achieve Greater Success and Liberty’: A Qualitative Study of Expanded Methadone Take-Home Access in Opioid Use Disorder Treatment,” Substance Abuse 43, no. 1 (2022): 1143-1150, doi: 10.1080/08897077.2022.2060438; S. M. Walters et al., “Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities,” Substance Use & Misuse 57, no. 7 (2022): 1144-1153, doi: 10.1080/10826084.2022.2064509; O. Amram et al., “The Impact of Relaxation of Methadone Take-Home Protocols on Treatment Outcomes In The COVID-19 Era,” American Journal of Drug & Alcohol Abuse 20 (2021): 1-8, doi: 10.1080/00952990.2021.1979991; S. Brothers, A. Viera, and R. Heimer, “Changes in Methadone Program Practices and Fatal Methadone Overdose Rates in Connecticut During COVID-19,” Journal of Substance Abuse Treatment 131 (2021): 108449, doi: 10.1016/j.jsat.2021.108449; X. A. Levander, et al., “Rural Opioid Treatment Program Patient Perspectives on Take-Home Methadone Policy Changes During COVID-19: A Qualitative Thematic Analysis,” Addiction Science & Clinical Practice 16, no. 1 (2021): 72, doi: 10.1186/s13722-021-00281-3.CrossRefGoogle ScholarPubMed

Substance Abuse and Mental Health Services Administration, Methadone Take-Home Flexibilities Extension Guidance, available at <https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/methadone-guidance> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Substance Abuse and Mental Health Services Administration, SAMHSA Proposes Update to Federal Rules to Expand Access to Opioid Use Disorder Treatment and Help Close Gap in Care, available at <https://www.samhsa.gov/newsroom/press-announcements/20221213/update-federal-rules-expand-access-opioid-use-disorder-treatment> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Levander, X. et al., “COVID-19-Related Policy Changes for Methadone Take-Home Dosing: A Multistate Survey of Opioid Treatment Program Leadership,” Substance Abuse 43, no. 1(2022): 633–639, doi: 10.1080/08897077.2021.1986768.CrossRefGoogle ScholarPubMed

Meyerson, B. E., et al. “Nothing Really Changed: Arizona Patient Experience of Methadone and Buprenorphine Access During COVID,” PLoS One 17, no. 10(2022): e0274094, doi: 10.1371/journal.pone.0274094.CrossRefGoogle ScholarPubMed

Doyle, S. and Baaklini, V., “President Signs Bipartisan Measure to Improve Addiction Treatment,” PEW Charitable Trusts, 2022, available at <https://www.pewtrusts.org/en/research-and-analysis/articles/2022/12/30/president-signs-bipartisan-measure-to-improve-addiction-treatment> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Substance Abuse and Mental Health Services Administration, Removal of DATA Waiver (X-Waiver) Requirement, 2023, available at <https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Hollander, M. et al., “Racial Inequity In Medication Treatment for Opioid Use Disorder: Exploring Potential Facilitators and Barriers to Use,” Drug & Alcohol Dependence 227 (2021): 108927, doi: 10.1016/j.drugalcdep.2021.108927; W. C. Goedel et al., “Association of Racial/Ethnic Segregation with Treatment Capacity for Opioid Use Disorder in Counties in the United States,” JAMA Network Open 3, no. 4 (2020): e203711, available at <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764663> (last visited June 1, 2023); P. A. Lagisetty et al., “Buprenorphine Treatment Divide by Race/Ethnicity and Payment,” JAMA Psychiatry 76, no. 9 (2019): 979-981, available at <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2732871> (last visited June 1, 2023).CrossRefGoogle ScholarPubMed

Hollander, M. et al., “Racial Inequity in Medication Treatment for Opioid Use Disorder: Exploring Potential Facilitators and Barriers to Use,” Drug & Alcohol Dependence 227 (2021): 108927, doi: 10.1016/j.drugalcdep.2021.108927; W. C. Goedel et al., “Association of Racial/Ethnic Segregation with Treatment Capacity for Opioid Use Disorder in Counties in the United States,” JAMA Network Open 3, no. 4(2020): e203711, available at <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764663> (last visited June 1, 2023).CrossRefGoogle ScholarPubMed

Amiri, S. et al., “Increased Distance was Associated with Lower Daily Attendance to an Opioid Treatment Program in Spokane County Washington,” Journal of Substance Abuse Treatment 93 (2018): 26–30, available at <https://pubmed.ncbi.nlm.nih.gov/30126538/> (last visited June 1, 2023); A. Rosenblum et al., “Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in The United States,” Journal of Environmental and Public Health (2011), available at <https://doi.org/10.1155/2011/948789> (last visited June 1, 2023).CrossRefGoogle Scholar

Joudrey, P. J. et al., “Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States,” JAMA 322, no. 13 (2019):1310–1312, available at <https://pubmed.ncbi.nlm.nih.gov/31573628/> (last visited June 1, 2023).CrossRefGoogle Scholar

Substance Abuse and Mental Health Services Administration, Opioid Treatment Program Directory (Rockville MD, 2021), available at <https://dpt2.samhsa.gov/treatment/directory.aspx> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

T. Anwar, M. Duever, and J. Jayawardhana, “Access to Methadone Clinics and Opioid Overdose Deaths in Georgia: A Geospatial Analysis,” Drug & Alcohol Dependence (2022): 238, doi: 10.1016/j.drugalcdep.2022.109565.CrossRefGoogle Scholar

Grimm CA, C. A., Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder (Washington DC: U.S. Department of Health and Human Services, Office of Inspector General, 2020), available at <https://oig.hhs.gov/oei/reports/oei-12-17-00240.pdf> (last visited June 1, 2023).Google Scholar

Drug Enforcement Administration, DEA Finalizes Measures to Expand Medication-Assisted Treatment (2021), available at <https://www.dea.gov/press-releases/2021/06/28/dea-finalizes-measures-expand-medication-assisted-treatment> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Joudrey, P. et al., “Pharmacy-Based Methadone Dispensing and Drive Time to Methadone Treatment in Five States within the United States: A Cross-Sectional Study,” Drug & Alcohol Dependence 211 (2020): 107968, doi: 10.1016/j.drugalcdep.2020.107968.CrossRefGoogle ScholarPubMed

Jones, C. M. et al., “Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, and Overdose Deaths - United States, 2002-2014,” Morbidity & Mortality Weekly Report 65, no. 26 (2016): 667–671, doi: https://doi.org/10.15585/mmwr.mm6526a2; P. Duffy and A. J. Mackridge, “Use and Diversion of Illicit Methadone – Under What Circumstances Does it Occur, and Potential Risks Associated with Continued Use of Other Substances,” Journal of Substance Use 19, no. 1-2 (2014): 48-55, doi:10.3109/14659891.2012.734539; B. Johnson and T. Richert, “Diversion of Methadone and Buprenorphine from Opioid Substitution Treatment: A Staff Perspective,” Journal of Psychoactive Drugs 46, no. 5 (2014): 427-435, doi:10.1080/02791072.2014.960109.Google ScholarPubMed

Duffy, P. and Mackridge, A.J., “Use and Diversion of Illicit Methadone – Under What Circumstances Does it Occur, and Potential Risks Associated with Continued Use of Other Substances,” Journal of Substance Use 19, no. 1-2 (2014): 48–55, doi:10.3109/14659891.2012.734539.CrossRefGoogle Scholar

National Academies of Sciences, Engineering, and Medicine, Medications for Opioid Use Disorder Save Lives: The National Academies Press (2019), available at <https://doi.org/10.17226/25310> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

National Academies of Sciences, Engineering, and Medicine, Methadone Treatment for Opioid Use Disorder: Improving Access through Regulatory and Legal Change: Proceedings of a Workshop (2022), available at <https://doi.org/10.17226/26635> (last visited June 1, 2023); R. Bonnie et al., “An Expedited Regulatory Strategy for Expanding Access to Methadone Treatment for Opioid Use Disorder,” Health Affairs Forefront (2022), available at <https://doi.org/10.1377/forefront.20220524.171269> (last visited June 1, 2023); Joudrey, P. J. et al., “Research Priorities for Expanding Access to Methadone Treatment for Opioid Use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report,” Substance Abuse 42, no. 3 (2022): 245–254, doi: 10.1080/08897077.2021.1975344.CrossRefGoogle Scholar

“Substance Abuse and Mental Health Services Administration (SAMHSA) Proposes Update to Federal Rules to Expand Access to Opioid Use Disorder Treatment and Help Close Gap in Care (2022) available at <https://www.samhsa.gov/newsroom/press-announcements/20221213/update-federal-rules-expand-access-opioid-use-disorder-treatment> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

S. Doyle, “Overview of Opioid Treatment Program Regulations by State,” Pew Charitable Trusts (2022) available at <https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2022/09/overview-of-opioid-treatment-program-regulations-by-state> (last visited June 1, 2023); Jackson, J. R. et al., “Characterizing Variability in State-Level Regulations Governing Opioid Treatment Programs,” Journal of Substance Abuse Treatment 115 (2020): 108008, doi: 10.1016/j.jsat.2020.108008.CrossRef+(last+visited+June+1,+2023);+Jackson,+J.+R.+et+al.,+“Characterizing+Variability+in+State-Level+Regulations+Governing+Opioid+Treatment+Programs,”+Journal+of+Substance+Abuse+Treatment+115+(2020):+108008,+doi:+10.1016/j.jsat.2020.108008.>Google Scholar

Jackson, J. R. et al., “State-Level Regulations and Opioid-Related Health Outcomes,” Drug and Alcohol Dependence 232 (2022): 109294, doi: 10.1016/j.drugalcdep.2022.109294.CrossRefGoogle ScholarPubMed

Alaska Admin. Code tit. 7, § 70.125(a)(1).Google Scholar

Idaho Admin. Code r. 16.07.17.415(2).Google Scholar

42 C.F.R. § 8.12(f)(2).Google Scholar

Id.Google Scholar

42 C.F.R. § 8.12(f)(5).Google Scholar

Ark. Code R. § 016.04.2-XII.Google Scholar

Amiri, S. et al., “Increased Distance was Associated with Lower Daily Attendance to an Opioid Treatment Program in Spokane County Washington,” Journal of Substance Abuse Treatment 93 (2018): 26–30, available at <https://pubmed.ncbi.nlm.nih.gov/30126538/> (last visited June 1, 2023), doi: 10.1016/j.jsat.2018.07.006; A. Rosenblum et al., “Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States,” Journal of Environmental and Public Health (2011), available at <https://doi.org/10.1155/2011/948789> (last visited June 1, 2023).CrossRefGoogle Scholar

Id. Google Scholar

National Academies of Sciences, Engineering, and Medicine, Medications for Opioid Use Disorder Save Lives, The National Academies Press (2019) available at <https://doi.org/10.17226/25310> (last visited June 1, 2023).CrossRef+(last+visited+June+1,+2023).>Google Scholar

42 C.F.R. § 8.12(f)(6).Google Scholar

908 Ky. Admin. Regs. 1:374, § 7(9)(c); 7(12)(e)(4).Google Scholar

105 Mass. Code Regs. 164.304(B)(2).Google Scholar

Frank, D. et al., “It’s Like ‘Liquid Handcuffs’: The Effects of Take-Home Dosing Policies on Methadone Maintenance Treatment (MMT) Patients’ Lives,” Harm Reduction Journal 18 (2021): 88, doi: 10.1186/s12954-021-00535-y; C. Strike and C. Rufo, “Embarrassing, Degrading, or Beneficial: Patient and Staff Perspectives on Urine Drug Testing in Methadone Maintenance Treatment,” Journal of Substance Use 15, no. 5 (2010): 303-312, available at <https://www.tandfonline.com/doi/full/10.3109/14659890903431603> (last visited June 1, 2023), doi.org/10.3109/14659890903431603.Google ScholarPubMed

Frank, id.Google Scholar

42 C.F.R. § 8.12(i)(2),(3).Google Scholar

Frank, supra note 47.Google Scholar

Substance Abuse and Mental Health Services Administration, Opioid Treatment Program (OTP) Guidance (Rockville, MD, 2020), available at <https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Substance Abuse and Mental Health Services Administration (SAMHSA) Extends the Methadone Take-Home Flexibility for One Year While Working Toward a Permanent Solution (2021), available at <https://www.samhsa.gov/newsroom/press-announcements/202111181000> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

Miss. Code R. § 24-3-53.5(L).Google Scholar

908 Ky. Admin. Regs. 1:374(7)(12)(j).Google Scholar

14 118 Me. Code R. 5 § 19.8.10.4.Google Scholar

N.H. Code Admin. R. He-A 304.23(o).Google Scholar

28 Pa. Code § 715.16(c)(3).Google Scholar

See Ark. Code R. § 016.04.2-XIV(B)(15); 16-6001 Del. Admin. Code § 14.7.Google Scholar

Davis, C. S. and Carr, D. H., “Legal and Policy Changes Urgently Needed to Increase Access to Opioid Agonist Therapy in the United States,” International Journal of Drug Policy 73 (2019): 42–48, available at <https://pubmed.ncbi.nlm.nih.gov/31336293/> (last visited June 1, 2023).CrossRefGoogle ScholarPubMed

Figgatt, M. C. et al., “Take-Home Dosing Experiences Among Persons Receiving Methadone Maintenance Treatment During COVID-19,” Journal of Substance Abuse Treatment 123 (2021): 108276, available at <https://pubmed.ncbi.nlm.nih.gov/33612201/> (last visited June 1, 2023); D. Frank, “A Chance to do it Better: Methadone Maintenance Treatment in the Age of COVID-19,” Journal of Substance Abuse Treatment 123 (2021): 108246, doi: 10.1016/j.jsat.2020.108246, available at <https://pubmed.ncbi.nlm.nih.gov/33612189/> (last visited June 1, 2023).CrossRefGoogle ScholarPubMed

42 C.F.R. § 8.12(i)(2)(vii).Google Scholar

42 C.F.R. § 8.12(i)(5).Google Scholar

Substance Abuse and Mental Health Services Administration, Federal Guidelines for Opioid Treatment Programs (Rockville MD, 2015): 79, available at <https://store.samhsa.gov/sites/default/files/d7/priv/pep15-fedguideotp.pdf> (last visited June 1, 2023).+(last+visited+June+1,+2023).>Google Scholar

21 U.S.C. § 823(g)(1); 42 C.F.R. § 8.11(a).Google Scholar

W. Va. Code Ann. § 16-5Y-12.Google Scholar

La. Admin. Code tit. 48, § 12907.Google Scholar

Ind. Code § 12-23-18-5.5.Google Scholar

440 Ind. Admin. Code 10-2-3(a)(5).Google Scholar

14 118 Me. Code R. 5 § 2.6.1.6.Google Scholar

Mo. Code Regs. tit. 9, § 30-3.132(1)(A)(3).Google Scholar

Ala. Admin. Code r. 410-2-4.Google Scholar

Mo. Code Regs. tit. 9, § 30-3.132(1)(A)(2).Google Scholar

440 Ind. Admin. Code 10-2-3(a)(1).Google Scholar

Ga. Code Ann. § 26-5-48.Google Scholar

Miss. Code R. § 24-2-2.4(E).Google Scholar

La. Admin. Code tit. 48, § 12907(K)(4)(a).Google Scholar

N.J. Rev. Stat. § 26:2H-11.1.Google Scholar

Ohio Admin. Code 5122-40-04(B).Google Scholar

Or. Rev. Stat. § 430.590.Google Scholar

Va. Code Ann. § 37.2-406(a), (f).Google Scholar

Amiri, S. et al., “Increased Distance was Associated with Lower Daily Attendance to an Opioid Treatment Program in Spokane County Washington,” Journal of Substance Abuse Treatment 93 (2018): 26–30, available at <https://pubmed.ncbi.nlm.nih.gov/30126538/> (last visited June 1, 2023).CrossRefGoogle Scholar

Wash. Rev. Code § 71.24.590.Google Scholar

14 118 Me. Code R. 5 § 19.8.4.3.Google Scholar

Abraham, A. J. et al., “Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care,” JAMA Health Forum 3, no. 11 (2022): e224001, doi: 10.1001/jamahealthforum.2022.4001.CrossRefGoogle ScholarPubMed

Woo, J. et al., “‘Don’t Judge a Book by Its Cover’: A Qualitative Study of Methadone Patients’ Experiences of Stigma,” Substance Abuse 11 (2017): 1178221816685087, doi: 10.1177/1178221816685087.Google Scholar

Alaska Admin. Code tit. 7, § 70.125(a)(1).Google Scholar

Idaho Admin. Code r. 16.07.17.415(2).Google Scholar